• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthCOVID-19 vaccines

Europe joins U.S. in pledging major vaccine donations to developing countries

By
David Meyer
David Meyer
Down Arrow Button Icon
By
David Meyer
David Meyer
Down Arrow Button Icon
May 21, 2021, 10:45 AM ET

The European Union will donate at least 100 million COVID-19 vaccine doses to developing countries this year, European Commission President Ursula von der Leyen announced Friday.

The EU’s top official also confirmed that the EU will invest €1 billion ($1.2 billion) in African vaccine manufacturing facilities to help the continent become more self-sufficient in fighting the coronavirus.

“We must step up efforts to give access to vaccines to low and middle income countries,” von der Leyen tweeted Friday. “We will do our part: #TeamEurope aims at donating at least 100 million doses to low and middle income countries by the end of 2021.”

A Commission spokesperson told Fortune the doses would be donated by EU member states such as Germany and France, either through the COVAX facility—a U.N.-backed program for distributing COVID vaccines to low and middle income countries—or bilaterally.

The move comes after the U.S. said Monday that it will donate 20 million Pfizer/BioNTech, Moderna and Johnson & Johnson vaccine doses to such countries, on top of the 60 million AstraZeneca doses it has already pledged to give, subject to a safety review. The U.S. will also make a “substantial portion” of those donations through COVAX.

Boosting jabs

Speaking Friday at the Global Health Summit, von der Leyen also noted that the EU’s “industrial partners”—the vaccine manufacturers—have pledged to make 1.3 billion doses available to low- and middle-income countries this year.

That includes 100 million doses from Moderna, 200 million from J&J, and 1 billion from Pfizer and BioNTech—which will also supply up to 1.8 billion doses to the EU from December through 2023, under a much-anticipated deal that was made official on Thursday. All the doses in the Pfizer/BioNTech agreement will be made in the EU, which has a population of just under 450 million.

Both the EU and the U.S. have made solid progress in their own vaccination campaigns—the U.S. more so, with nearly half the population having received at least one dose; a third of people in the EU can claim the same.

In poorer parts of the world, it’s a very different story. Just over 10% of people in India have received a first dose, while in Africa the figure stands at a mere 1.4%.

This inequality has for months been criticized by everyone from the World Health Organization to the International Monetary Fund and the Pope, and it is only recently that rich countries have been making their pledges.

The EU has, however, already promised €500 million in grant funding and guarantees to the COVAX facility. The U.S. has donated $2 billion to COVAX in recent months.

Patents and politics

The Biden administration has also given its backing to the increasingly popular idea of waiving patents on COVID-19 vaccines, in order to stimulate production around the world. The EU remains opposed to that notion, instead arguing that the compulsory licensing of vaccine patents could be the way forward.

Ultimately, von der Leyen said Friday, all regions need to be able to make their own vaccines.

“Preventing future health emergencies means strengthening capacities throughout the world,” she said. “Today, Africa imports 99% of its vaccines. This has to change. Therefore, Team Europe is launching an initiative with African partners to develop vaccine production in Africa. The initiative will develop a number of regional hubs distributed across the continent and it will draw on the full toolbox of Team Europe, including €1 billion of investment.”

Apart from the moral imperative and the fact that vaccinating the world is the only way to fight the emergence of dangerous new COVID variants, there is also a diplomatic motive behind the U.S. and EU pledges. China and Russia have been amassing a great deal of soft power through their supply of vaccines to poorer countries, and the West has catching-up to do.

The U.S.’s pledge on Monday inspired a grudging editorial in the Chinese Communist Party’s Global Times, which noted that “China has been offering vaccines and medical supplies to developing countries for nearly half a year” while sneering that “Chinese observers…expressed doubts over whether developing countries in urgent need of vaccines will actually receive them considering the U.S.’ stock-in-trade of sloganeering despite inaction.”

Our mission to make business better is fueled by readers like you. To enjoy unlimited access to our journalism, subscribe today.
About the Author
By David Meyer
LinkedIn icon
See full bioRight Arrow Button Icon

Latest in Health

Dr. Javier Cárdenas is the director of the Rockefeller Neuroscience Institute NeuroPerformance Innovation Center.
Commentaryconcussions
Fists, not football: There is no concussion protocol for domestic violence survivors
By Javier CárdenasDecember 12, 2025
1 hour ago
Healthmeal delivery
The Best Meal Delivery Services for Weight Loss of 2025: Dietitian Approved
By Christina SnyderDecember 11, 2025
21 hours ago
Best protein lead image
HealthDietary Supplements
The 8 Best Protein Powders of 2025: How to Choose, According to an RD
By Christina SnyderDecember 9, 2025
3 days ago
Transparent Labs Creatine HMB as best creatine
HealthDietary Supplements
The Best Creatine Supplements of 2025: Tested and Approved
By Christina SnyderDecember 9, 2025
3 days ago
Jon Rosemberg
CommentaryProductivity
The cult of productivity is killing us
By Jon RosembergDecember 9, 2025
3 days ago
Trump
CommentaryTariffs and trade
AI doctors will be good at science but bad at business, and big talk with little action means even higher drugs prices: 10 healthcare predictions for 2026 from top investors
By Bob Kocher, Bryan Roberts and Siobhan Nolan ManginiDecember 9, 2025
3 days ago

Most Popular

placeholder alt text
Success
At 18, doctors gave him three hours to live. He played video games from his hospital bed—and now, he’s built a $10 million-a-year video game studio
By Preston ForeDecember 10, 2025
2 days ago
placeholder alt text
Success
Palantir cofounder calls elite college undergrads a ‘loser generation’ as data reveals rise in students seeking support for disabilities, like ADHD
By Preston ForeDecember 11, 2025
23 hours ago
placeholder alt text
Investing
Baby boomers have now 'gobbled up' nearly one-third of America's wealth share, and they're leaving Gen Z and millennials behind
By Sasha RogelbergDecember 8, 2025
4 days ago
placeholder alt text
Economy
‘We have not seen this rosy picture’: ADP’s chief economist warns the real economy is pretty different from Wall Street’s bullish outlook
By Eleanor PringleDecember 11, 2025
1 day ago
placeholder alt text
Uncategorized
Transforming customer support through intelligent AI operations
By Lauren ChomiukNovember 26, 2025
16 days ago
placeholder alt text
Success
What it takes to be wealthy in America: $2.3 million, Charles Schwab says
By Sydney LakeDecember 11, 2025
1 day ago
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.